Croatian researchers isolated the full, larger peptide BPC in 1998 from gastric juices and found the 15 amino acid sequence, BPC-157 to be the active part responsible for its clinical effects (the story of how it was discovered is fascinating, but that is a conversation for a different day if there is enough interest, let me know below)
Typical doses: GHK-Cu 12 mg + BPC-157 250500 mcg + TB-500 250500 mcg per day during the active phase
Mark your bottle with the reconstitution date and discard after this period

certificate of analysis available on request Research Applications Suitable Laboratory Uses for FOXO4-DRI FOXO4-p53 protein-protein interaction disruption assays CO-IP, competitive binding, and proximity ligation studies Selective senescent cell apoptosis induction SA--gal, p16, p21, p53 marker-confirmed senescent populations p53 TAD2 binding, phospho-p53 (Ser15) nuclear exclusion, and mitochondrial translocation pathway studies BAX/BCL-2/Caspase-3 intrinsic apoptosis cascade investigations in senescent cell models SASP characterisation and suppression IL-6, IL-8, MMP, VEGF, CXCL2/3 secretome studies Tissue-specific senescence models fibroblasts, endothelial cells, Leydig cells, chondrocytes, keloid fibroblasts Vascular ageing pathway research endothelial senescence, aortic function, and ROS pathway studies Senescent cancer cell biology and drug resistance pathway research Comparative senolytic research FOXO4-DRI vs